Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology ...
High demand by institutional investors enables early termination of public offering period Subscription period via the Formycon website is now scheduled to end on 26 June 2025, at 11:59 p.m. CEST ...
AHMEDABAD, India and PLANEGG-MARTINSRIED, Germany, Dec. 9, 2025 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...
Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last Patient-In) ...
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering ...
Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next ...
Approval and commercial launch of FYB201 as well as ATHOS transaction mark transformative fiscal year Group revenues increase to Euro 42.5 million (2021 IFRS: Euro 36.6 million) and include first ...
This week Formycon AG (“Formycon”) announced positive preliminary efficacy and safety data from the VESPUCCI Phase III clinical trial for FYB202, Formycon’s biosimilar version of STELARA (ustekinumab) ...
Formycon AG (DE:FYB) partner Bioeq IP (Bioeq) plans to file FYB201, a Lucentis biosimilar candidate, to treat neovascular age-related macular degeneration (nAMD) with the FDA imminently in Q419. The ...
(RTTNews) - Formycon AG (0W4N.L) along with its commercialization partner Fresenius Kabi, Monday announced that the U.S. Food and Drug Administration designated FYB202/Otulfi as interchangeable with ...
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results